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The incidence of breast cancer has been increasing 
recently worldwide. Therefore, the search for the novel 
techniques for diagnosis and treatment as well as the 
studies elucidating pathogenetic mechanisms associ-
ated with tumorogenesis and delineating the molecular 
markers useful for diagnostics and monitoring of the 
disease are the topical issues of the day.
The tumor develops in the setting of the metabolic 
disorders. In particular, tumor growth is accompanied 
by the impaired lipid metabolism. Lipids as the con-
stituents of plasma membranes, energy substrate 
and signal molecules participate actively in neocar-
cinogenesis.
Metabolic impairments form the basis of metabolic 
syndrome. In 2005, International Diabetes Federation 
referred to metabolic syndrome as one of the major 
problems in modern medicine contributing to the 
increased total death rate in population. Moreover, 
metabolic syndrome is associated with increased risk 
of tumor growth and unfavorable prognosis for cancer 
patients [1, 2].
In economically developed countries, the preva-
lence of metabolic syndrome is 25–35%. This figure 
increases up to 42–45% among the patients aged 
over 60. And one should take into account that cancer 
prevalence is also maximal in the persons of the older 
age group.
The principal symptoms of metabolic syndrome 
are such as follows:
• Abdominal obesity with waist exceeding 88 cm
• Dyslipidemia with triglycerides >1.69 mmol/L and 
cholesterol of the high density lipids >1.04 mmol/L
• Hyperglycemia with fasting glucose in the periph-
eral blood >6.1mmol/L
• Arterial hypertension with arterial blood pressure 
>130/85 mm Hg/
The presence of at least 3 signs of the 4 listed above 
allows one to diagnose metabolic syndrome.
The metabolic syndrome with accompanying in-
sulin resistance and dyslipidemia are associated with 
the increased risk of colorectal cancer, endometrial 
cancer, gall bladder cancer, prostate cancer, cancer 
of pancreas and breast cancer [1–4]. At present, the 
role of many molecular factors of the metabolic syn-
drome that are pertinent to carcinogenesis has been 
already clarified, namely insulin, insulin-like growth 
factor, leptin, tumor necrosis factor, cholesterol, aro-
matase, etc.
The spectrum of blood serum lipids in the patients 
with breast cancer in the setting of metabolic syn-
drome is different from that in the healthy women [4, 
5]. The role of the impaired lipid metabolism as the 
triggers of the molecular mechanisms of neocarcino-
genesis has been proven.
The following alterations of the spectrum 
of blood serum lipids in the patients with breast 
cancer in the setting of metabolic syndrome have 
been found out:
There are plenty researches [4–6] devoted 
to breast cancer in the setting of metabolic syndrome. 
According to various data, in 20–40% of the patients 
with breast cancer (setting apart the familial and 
hereditary breast cancer), the signs of the metabolic 
syndrome are lacking.
Therefore, we have attempted to study the char-
acteristic features of spectrum of blood serum lipids 
in the patients with breast cancer without metabolic 
syndrome and to assess the dynamics of the param-
eters of the spectrum of blood serum lipids following 
the cytostatic therapy.
Among 100 patients with breast cancer stage ІІВ 
(T2N1M0,T3N0M0) aged 30–60 treated in Kyiv munici-
pal clinical oncological center, 67 patients were with 
the signs of metabolic syndrome while in 23 patients 
the metabolic syndrome was not revealed.
23 patients with breast cancer without metabolic 
syndrome and 13 healthy women were included into 
the study. The clinical characteristics of patients 
and controls included in to the study are presented 
in Table 1.
Table 1. Clinical characteristic of patients with breast cancer without met-
abolic syndrome and healthy women
Parameter Control (n=13) Patients (n=23)
Age (years) 41.3±2.7 44.1±4.7
Body height (cm) 167.1±1.3 165.8±1.1
Body mass (kg) 61.2±3.9 65.3±5.0
Index of body mass (kg/m2) 23.8±1.1 25.4±1.3
Circumference of abdomen (cm) 70.8±1.6 72.1±2.2
Arterial blood pressure (mm Hg) 118±1.8/70±0.6 115±3.2/9±1.4
The group of patient and the control group were 
similar according to stated parameters.
In all patients and healthy persons participating 
in the study, the fasting venous blood was sampled for 
assaying total cholesterol, triglycerides, and glucose 
content (Table 2).*Correspondence: E-mail — timovska79@gmail.com
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Table 2. Biochemical parameters of blood in the patients with breast can-
cer without metabolic syndrome and healthy women
Parameter  (mmol/L) Control group (n=13) Patients (n=23)
Total cholesterol 4.9±0.7 5.2±0.5
Triglycerides 1.5±0.5 1.4±0.7
Glucose 4.4±0.2 4.5±0.3
The biochemical parameters in both groups were 
within the normal ranges, that coincide with data 
of other authors [7].
Therefore, in the patients with breast cancer with 
normal body mass, without abdominal obesity and 
without arterial hypertension, the blood content of total 
cholesterol, triglycerides, and glucose do not deviate 
from the normal values.
Then we assayed the total lipids of blood serum 
by thin layer chromatography using micromethod 
of detection. The percent content of phospholipids, 
di- and triglycerides, and cholesterol esters was as-
sessed. The results are given in Table 3.
Table 3. Content (%) of total lipids in blood serum in the patients with 
breast cancer without metabolic syndrome and healthy women
Group
Parameters
Phospho-
lipids
Choles-
terol
Diglycer-
ides
Triglycer-
ides
Cholester-
ol esters
Patients 15.9±2.4 23.4±1.9 7.2±1.0 32.7±2.8 20.7±2.1
Controls 18.3±1.8 20.9±1.8 5.0±1.0 24.6±3.6 31.2±3.4
As it can be seen, the content of phospholipids and 
cholesterol in the patients with breast cancer does not 
differ from that in the healthy women. Meanwhile, the 
content of di- and triglycerides in the blood serum 
of the patients is inferior to that in healthy women; the 
content of cholesterol esters in the patients is superior 
to that in healthy women (Fig.1–4).
As to triglycerides representing the energy substrate 
used in the pathological conditions, one may suggest 
that the decrease in the content of triglycerides in the 
blood serum of the patients with breast cancer may 
be associated with their active utilization by cancer cells.
Although the absolute content of total cholesterol 
and triglycerides (in mmol/L) in the patients with breast 
cancer without metabolic syndrome is within the nor-
mal range, the redistribution between the components 
of lipidogram is evident with the increase in cholesterol 
esters content and decrease in triglyceride content 
as compared to that in the healthy controls.
The spectrum of the individual phospholipids (ly-
sophosphatidyl choline, sphyngomyelin, phosphatidyl 
ethanolamine, phosphatidyl inositol) was assessed 
by thin layer chromatography. The results are given 
in Table 4.The difference between the parameters 
under study was insignificant.
Table 4. Content (%) of individual lipids in blood serum in the patients 
with breast cancer without metabolic syndrome and healthy women
Groups
Parameters
Lysophos-
phatidyl 
choline
Sphyngo-
myelin
Phospha-
tidyl cho-
line
Phospha-
tidyl etha-
nolamine
Phospha-
tidyl ino-
sitol
Control 10.5±0.7 19.5±1.2 52.0±2.2 11.1±0.3 6.8±1.1
Patients 8.9±0.8 20.0±2.1 58.1±3.5 10.5±2.0 2.3±1.1
All the patients with breast cancer stage ІІВ without 
metabolic syndrome were treated with two 21-day 
courses of neoadjuvant polychemotherapy according 
to CAF regimen (Doxorubicin, Cyclophosphamide, 
5-fluorouracil). Then the analysis of the above bio-
chemical parameters was repeated (Table 5).
Table 5. Content (%) of total lipids in blood serum in the blood serum 
of patients with breast cancer without metabolic syndrome prior to and af-
ter two courses of neoadjuvant polychemotherapy
Parameters
Phospho-
lipids
Choles-
terol
Diglycer-
ides
Triglycer-
ides
Cholester-
ol esters
Prior to treatment 18.3±1.8 20.9±1.8 5.0±1.0 24.6±3.6 31.2±3.4
After treatment 15.1±2.4 18.3±1.5 4.8±1.3 33.4±5.3 28.5±3.1
Fig. 1. The spectrum of blood serum lipids of healthy woman 
FNI, 42 years old.
Fig. 2. The spectrum of blood serum lipids of healthy woman 
YNO, 34 years old
Fig. 3. The spectrum of blood serum lipids of breast cancer 
patient ZSV, 38 years old
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Fig. 4. The spectrum of blood serum lipids of breast cancer 
patients GNN, 40 years old. 1 — phospholipids, 2 — cholesterol, 
3-free fatty acids, 4 — triglycerides, 5 — cholesterol esters 
The differences were not statistically significant. 
The trend to increasing triglyceride content and de-
creasing content of cholesterol esters and phospho-
lipids was found out.
The dynamics of these parameters in the patients with 
tumors chemosensitive to chemotherapy was analyzed. 
The tumor was considered as chemosensitive one when 
regression exceeded 30% according to mammography 
findings and pathomorphological response exceeded 
that of grade II assessed upon the histological study 
of the resected tumors. The decrease in the content 
of cholesterol esters and increase in the content of tri-
glycerides was evident in 70% of the patients with tumors 
chemosensitive to chemotherapy and 26% with resistant 
tumors. Moreover, in the patients with resistant tumors 
the level of phospholipids was unchanged or even re-
duced. In the patients with chemosensitive large tumors, 
the blood content of phospholipids increased suggesting 
the destruction of the bulk of chemosensitive cancer cells 
and the release of phospholipids to the blood circulation.
We have also studied the serum blood content 
of the individual lipids in the patients with breast cancer 
prior to and after two courses of neoadjuvant polyche-
motherapy. The results are given in Table 6.
Table 6. Content (%) of individual lipids in blood serum in the blood se-
rum of patients with breast cancer without metabolic syndrome prior 
to and after two courses of neoadjuvant polychemotherapy
Groups
Parameters
Lysophos-
phatidyl 
choline
Sphyngo-
myelin
Phospha-
tidyl cho-
line
Phospha-
tidyl etha-
nolamine
Phospha-
tidyl ino-
sitol
Prior to treatment 8.9±0.8 20.0±2.1 58.1±3.5 10.5±2.0 2.3±1.1
After treatment 9.8±1.4 23.2±1.8 54.6±2.8 8.5±1.2 3.9±1.3
In general group of the patients, the parameters 
stated above were not significantly different when 
assessed prior to the treatment and after two courses 
of neoadjuvant polychemotherapy. The trend to in-
creasing phosphatidyl inositol content and decreas-
ing content of phosphatidyl choline and phosphatidyl 
ethanolamine was observed.
In the cases of chemosensitive breast cancer, statisti-
cally significant reduction of phosphatidyl ethanolamine 
was recorded. The content of phosphatidyl inositol was 
higher in the patients with the chemosensitive tumors 
(both prior to and after neoadjuvant polychemotherapy).
Phosphatidyl inositol (precursor of inositol triphos-
phate) does not represent the structural component 
of plasma membrane. This substance is a signal molecule 
stimulating a set of metabolic processes related to cell 
proliferation. The increased blood serum phosphatidyl ino-
sitol content in then patients with cancer chemosensitive 
to the treatment may be considered as indirect evidence 
of increased proliferative activity of such cancer cells.
Phosphatidyl ethanolamine is classified as canabi-
noid. These molecules stimulate proliferation affecting 
the growth receptors of cell membranes. The reasonable 
explanation of the increased phosphatidyl ethanolamine 
content is not available in the literature. One may suggest 
that upon the reduction of the number of cancer cells due 
to chemotherapy, in the resistant clones the proliferation 
potential increases. Phosphatidyl ethanolamine may be re-
garded as the marker of such increased poliferative activity.
Phosphatidyl choline is a product of the cancer cell 
metabolism. In some studies, the content of phospha-
tidyl choline is reduced only upon completion of the 
complex treatment. Therefore, the trend to decreasing 
content of this substance in the present study does not 
contradict the results of other authors [5, 8, 9].
In conclusion, our pilot study has confirmed the signifi-
cance of lipids in carcinogenesis. Breast cancer patients 
with no obvious metabolic disorder exhibit certain variations 
in their serum blood lipid spectrum associated with onco-
logic disease. However, additional immunohistochemical 
research is required identifying the markers of prolifera-
tion in tumor cells in order to confirm our assumptions.
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